Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study

Executive Summary

Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.

Advertisement

Related Content

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)
Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel